Eupraxia Pharmaceuticals, Inc. · TSX:EPRX
Eupraxia Pharmaceuticals — World Congress of Gastroenterology @ Australian Gastroenterology Week 2025
8 slides from Eupraxia Pharmaceuticals's conference presentation, September 2025
Slide 1: Updated Dose Escalation Results From RESOLVE, Phase 1b/2a Study of EP-104GI
Updated Dose Escalation Results From RESOLVE, An Ongoing Phase 1b/2a Study of EP-104GI (Long-Acting Fluticasone Propionate Injectable Suspension) For Eosinophilic Esophagitis Nguyen N.1, Malone A.2, Helliwell J. 2, Kowalski M. M. 2, Ko H. H.3, Holtmann G.4, Afif W.5, Bredenoord A. J.6, Dellon E. S.7
Slide 2: Potential of EP-104GI In Eosinophilic Esophagitis
Potential of EP-104GI In Eosinophilic Esophagitis Sub-Epithelial Eosinophilic Esophagitis Pathogenesis o Local inflammation in eosinophilic esophagitis (EoE) leads to burdensome symptoms such as dysphagia1 o Novel treatments with improved efficacy or duration are needed. o The broad anti-inflammator
Slide 3: RESOLVE Trial (NCT05608681)
RESOLVE Trial (NCT05608681) Phase 1b/2, multicenter, open-label, dose-escalation and optimization trial to evaluate the safety, tolerability, feasibility, pharmacokinetics, and efficacy of EP-104GI in adults with EoE o EP-104GI is injected in the esophageal layers once, at baseline during endoscopy,
Slide 4: Low And Constant Plasma Fluticasone Levels Following Administration
Low And Constant Plasma Fluticasone Levels Following Administration 100 100 o Systemic levels of fluticasone remain near 4×1mg Plasma Fluticasone Concentration 90 80 8×1mg constant and <20 pg/mL shortly (2 weeks) 80 8×2.5mg following an initial peak 70 60 12×2.5mg 60 12×4mg 40 (pg/ml) 16×4mg 50 20 4
Slide 5: No Dose-Limiting Toxicity Observed to Date
No Dose-Limiting Toxicity Observed to Date o Serum concentrations of glucose and cortisol remained stable following EP-104GI administration o No serious adverse events reported o Most treatment-emergent adverse events unlikely related to EP-104GI* Concentration (nmol/l) 1,000 Cortisol Serum 800 600
Slide 6: Reduction In Inflammation And Histological Features
Reduction In Inflammation And Histological Features o Overall, inflammation markers and histological scores show an escalating response for doses reported to date o Week 36: Improvements >30% in Esophageal Biopsies With Peak Eosinophil Count (PEC) ≤6/hpf o Week 36: Improvements >45% in EoE Histology
Slide 7: Improvements In Dysphagia Up to Weeks
Improvements In Dysphagia Up to 36 Weeks o Sustained, long-term improvements in patient-reported dysphagia following single administration of EP-104GI Mean Change From Baseline In SDI Score 1.0 o Week 24: Most cohorts demonstrate a 4×1mg 0.0 8×1mg response in Straumann Dysphagia Index ≥3 1 8×2.5mg -
Slide 8: Conclusions
Conclusions o EP-104GI administration has been feasible, safe and well tolerated to date, with no gastrointestinal candidiasis, signs of adrenal suppression, or other dose-limiting toxicity reported o Escalating improvements after a single administration of EP-104GI in esophageal inflammation and lo